Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Receivables (2022 - 2025)

Axsome Therapeutics' Receivables history spans 4 years, with the latest figure at $246.7 million for Q4 2025.

  • For Q4 2025, Receivables rose 58.63% year-over-year to $246.7 million; the TTM value through Dec 2025 reached $246.7 million, up 58.63%, while the annual FY2025 figure was $246.7 million, 58.63% up from the prior year.
  • Receivables for Q4 2025 was $246.7 million at Axsome Therapeutics, up from $196.5 million in the prior quarter.
  • Across five years, Receivables topped out at $246.7 million in Q4 2025 and bottomed at $16.2 million in Q2 2022.
  • The 4-year median for Receivables is $101.4 million (2024), against an average of $112.6 million.
  • The largest annual shift saw Receivables skyrocketed 413.75% in 2023 before it soared 44.88% in 2024.
  • A 4-year view of Receivables shows it stood at $46.8 million in 2022, then soared by 102.62% to $94.8 million in 2023, then soared by 64.0% to $155.5 million in 2024, then surged by 58.63% to $246.7 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Receivables are $246.7 million (Q4 2025), $196.5 million (Q3 2025), and $198.8 million (Q2 2025).